The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) was established in 1997 and since its inception has obtained over 10,000 samples procured from 4,000 consented patients at OSU. The LTBSR successfully facilitates translation of basic research in leukemia to the clinical setting by making available an extensive repository of tissue samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. The infrastructure of the OSUCCC LTBSR is supported by outstanding institutional support and is directed by Dr. Guido Marcucci, a physician-scientist and an established senior investigator in translational research in leukemia. He oversees a highly-trained staff with extensive experience in leukemia research that provides a full array of unique services to support high quality leukemia research. The LTBSR consists of a large and unique leukemia tissue repository, including both leukemic tissue and normal tissue germ line DNA, accompanied in all cases with complete pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. In addition, all the essentials of effective leukemia tissue bank management are very well-developed, including the activities of tissue collection, best practices, quality control of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical information, data entry and database management, and patient consent and confidentiality. The LTBSR leverages key partnerships within .the OSUCCC and efficient coordination with other key OSUCCC Shared Resources, to provide fundamental support of a key research mission of the OSUCCC: to produce high-quality basic and clinical research in hematological malignancy. While separated with regard to the mechanisms of collecting samples and allocation of samples to investigators, the LTBSR and the OSUCCC Biorepository and Biospecimen Shared Resource for solid tumors are governed by the same operational procedures with regard to commitment to the OSUCCC research mission and patients'confidentiality. The procedures for prioritizing and distributing tissue to a large base of investigators within the OSUCCC are effectively in place. The success in managing this large leukemia tissue resource is well-supported by the broad usage of this resource by >92% OSUCCC members and by high-impact publications (e.g.. Cell, Cancer Cell, Journal Clinical Oncology, Blood) by OSUCCC investigators in which the LTBSR has played a significant role.

Public Health Relevance

The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) leverages outstanding institutional support to facilitate the translation of basic research in leukemia to the clinical setting by making available an extensive repository of blood and bone marrow samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. Services provided through the LTBSR promote best practices and provide quality control of specimens from procurement to their use in high quality cancer research discovery, while maintaining patient consent and confidentiality.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric et al. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res 36:713-9
Eloy, Josimar O; Petrilli, Raquel; Topan, José Fernando et al. (2016) Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 141:74-82
Byrd, John C; Flynn, Joseph M; Kipps, Thomas J et al. (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127:79-86
Datta, Jharna; Islam, Mozaffarul; Dutta, Samidha et al. (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 56:32-9
Wang, Hai; Agarwal, Pranay; Zhao, Shuting et al. (2016) Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 97:62-73
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Rai, K; Pilarski, R; Cebulla, C M et al. (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89:285-94
Kerrigan, Kathleen; Shoben, Abigail; Otterson, Gregory (2016) Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer 17:523-527
DiSilvestro, David J; Melgar-Bermudez, Emiliano; Yasmeen, Rumana et al. (2016) Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese Mice. PLoS One 11:e0153198
Terakawa, Jumpei; Rocchi, Altea; Serna, Vanida A et al. (2016) FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct. Mol Endocrinol 30:783-95

Showing the most recent 10 out of 1929 publications